POTENSI PENGGUNAANCAIRANSEREBROSPINAL-AMYLOID42 UNTUK DIAGNOSIS DINI PENYAKIT ALZHEIMER:

Puspa Gracella Tambunan, Nia Maylani Hutagaol, Sekar Ayu Wirawan

Abstract


Penyakit Alzheimer merupakan salah satu penyakit neurod egeneratif yang kompleks secara klinis dan patologis. Hingga saat ini belum ada gold standard dalam penegakan diagnosa penyakit Alzheimer dan kurang efektifnya pengobatan menjad i sebuah celah kesempat an perkembangan ilmu penget ahuan d alam biomolekuler. Pencarian literatur dilakukan dengan beberapa database elektronik. Hasil didapatkan bahwa dalam kelompok diagnostic, kadar plasma Ab42 lebih rendah pada pasien penyakit Alzheimer dibandingkan dengan kelompok control, SCD, dan MCI dengan meninjau AUC tiap studi inklusi. Kesimpulan studi ini adalah didapatkan bahwa ekspresi Amyloid Beta 42 secara signifikan ditemukan di CSF dan memiliki akurasi diagnostik yang sangat baik dalam membedakan pasien dengan Penyakit Alzheimer dan orang sehat. 


Keywords


Cairan Serebrospinal β-amyloid 42, CSF Aβ42, Penyakit Alzheimer, Biomaker

Full Text:

PDF

References


Alzheimer's Association. 2016 Alzheimer's d isease facts and figures. Alzheimer's & Dementia. 2016 Apr 1;12(4):459-509

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y , Jorm A. Global prevalence of dementia: a Delphi consensus study. The lancet. 2005 Dec 17;366(9503):2112-7

Kementrian Kesehatan RI. Lansia yang Sehat, Lansia yang Jauh dari Demensia [Internet]. Pusat Analisis Determnan Kesehatan Kementrian Kesehatan RI. 2016 [Dikunjungi 6 Agustus 2020]. Tersedia di : https://www.kemkes.go.id/articl e/view/16031000003/menkes- lansia-yang-sehat-lansia-yang- jauh-d ari-d emensia.ht ml Mantzavinos V , Alexiou A. Biomarkers for Alzheimer' s d isease d iagnosis. Current Alzheimer Research. 2017 Nov 1;14(11):1149-54

The Need for Early Detection and Treatment in Alzheimer’ s Disease. (2016). EBioMedicine, 9, 1–2. d oi:10.1016/j.ebiom.2016.07.00 1

Counts SE, Ikonomovic MD, Mercado N, Vega IE,Mufson EJ. Biomarkers for the early d et ect ion and progression of Alzheimer’s d isease. Neurotherapeutics. 2017 Jan 1;14(1):35-53.

Counts SE, Ikonomovic MD, Mercado N, Vega IE,Mufson EJ. Biomarkers for the early d etection and progression of Alzheimer’s d isease. Neurotherapeutics. 2017 Jan 1;14(1):35-53.

Slot RER et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s d isease dementia. 2019 March: 15(3): 465-476

Kirsebom BE. Dementia Disease Initiation: Identifying subjective cognitive decline (SCD) due to Alzheimer’s disease.

Janelid ze S, Stomrud E, Palmqvist S, Zetterberg H, Van Westen D, Jeromin A, Song L, Hanlon D, Hehir CA, Baker D, Blennow K. Plasma β-amyloid in Alzheimer’s disease and vascular disease. Scientific reports. 2016 May 31;6(1):1-1.

Mantzavinos V , Alexious A Biomarkers for Alzheimer’s Disease Diagnosis. 2017: 4:1149-1154

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta- analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015 Dec 1;4(1):1.

Kurlowicz L, Wallace M. The mini-ment al st at e examinat io n (MMSE). Journal of gerontological nursing. 1999 May 1;25(5):8-9.

Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of d iagnost ic accuracy st ud ies. Annals of internal med icine. 2011 Oct 18;155(8):529-36.

Sleegers K, Bettens K, De Roeck A, V an Cauwenberghe C, Cuyvers E, Verheijen J, Struyfs H, Van Dongen J, Vermeulen S, Engelborghs S, Vandenbulcke M. A 22-single nucleot id e polymorphism Alzheimer' s disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. Alzheimer's & Dementia. 2015 Dec 1;11(12):1452-60.

Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's & Dementia. 2018 Nov 1;14(11):1470-81.

Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytica l platforms for cerebrospinal fluid measures of {beta}. Amyloid. 2011;1(42):1137-44.

Pottiez G, Yang L, Stewart T, Song N, Aro P, Galasko DR, Quinn JF, Peskind ER, Shi M, Zhang J. Mass-spectrometry- based method to quantify in parallel tau and amyloid β 1–42 in CSF for the diagnosis of Alzheimer’s disease. Journal of proteome research. 2017 Mar 3;16(3):1228-38.

Pan C, Korff A, Galasko D, Ginghina C, Peskind E, Li G, Quinn J, Montine TJ, Cain K, Shi M, Zhang J. Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ 42 using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's d isease. 2015 Jan 1;45(3):709-19.

Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toled o JB, Boller A, Bekisz J, Chandrasekaran K, Wood EM. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2013 Feb 1;84(2):163-9.

Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, van Westen D, Stomrud E, Minthon L, Blennow K, Hansson O.CSFAb42/Ab40andAb 42/A b 38 ratios: better diagnostic markers of Alzheimer d isease. Ann. Clin. Transl. Neurol. 2016;3.

Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner M, Alzheimer's Disease Neuroimaging Initiative. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of clinical and t ranslat iona l neurology. 2014 Aug;1(8):534- 43.

Baiardi S, Abu‐Rumeileh S, Rossi M, Zenesini C, Bartoletti‐ Stella A, Polischi B, Capellari S, Parchi P. Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's d isease pathology better than Aβ42 in rapidly progressive dementias. Annals of

the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s d isease d ement ia in mild cognitive impairment . Alzheimer's research & therapy. 2018 Dec 1;10(1):33.

Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Minthon L, Blennow K, Olsson M, Hansson O, Alzheimer' s Disease Neuroimaging Initiative, Swedish BioFINDER Study Group. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer d isease. Neurology. 2015 Oct 6;85(14):1240-9.

Bibl M, Esselmann H, Lewczuk P, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Mollenhauer B. Combined analysis of CSF tau, Aβ42, Aβ1– 42% and Aβ1–40ox% in Alzheimer's d isease, d ementia with Lewy bodies and Parkinson's d isease d ementia. International journal of Alzheimer's disease. 2010;2010.

Roe CM, Fagan AM, Williams MM, Ghoshal N, clinical neurology. 73. and 2019 translat iona l Feb;6(2):263 -

Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas- Pereira M, Beato-Coelho J, Duro D, Almeida MR, Oliveira CR. Addition of the Aβ42/40 ratio to Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC. I mproving CSF biomarke r accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 2011 Feb 8;76(6):501-10.

Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P. Amyloid β (1–42) and phosphorylated tau in CSF as markers f or early-onse t Alzheimer d isease. Neurology. 2004 May 11;62(9):1580-4.

Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner M, Alzheimer's Disease Neuroimaging Initiative. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of clinical and t ranslat iona l neurology. 2014 Aug;1(8):534- 43.

V anmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, Davidsson P, Blennow K. Cerebrospinal fluid τ and β-amyloid (1-42) in dementia disorders. Mechanisms of ageing and development. 2001 Nov 1;122(16):2005-11.

Bouallègue FB, Mariano- Goulart D, Payoux P, Alzheimer’s Disease Neuroimaging Initiative (ADNI. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognit ive impairmen t prognosis using t he A D N I -2 database. Alzheimer's research & therapy. 2017 Dec 1;9(1):32.

Llorens F, Schmitz M, Knipper T, Schmidt C, Lange P, Fischer A, Hermann P, Zerr I. Cerebrospinal fluid biomarkers of Alzheimer's d isease show different but partially overlapping profile compared to vascular dementia. Frontiers in aging neuroscience. 2017 Sep 12;9:289.

Almdahl IS, Lauridsen C, Selnes P, Kalheim LF, Coello C, Gajdzik B, Møller I, Wettergreen M, Grambaite R, Bjørnerud A, Bråthen G. Cerebrospinal fluid levels of amyloid beta 1-43 mirror 1-42 in relation to imaging biomarkers of Alzheimer’ s d isease. Front iers in aging neuroscience. 2017 Feb 7;9:9.

Shi M, Tang L, Toledo JB, Ginghina C, Wang H, Aro P, Jensen PH, Weintraub D, Chen- Plotkin AS, Irwin DJ, Grossman M. Cerebrospinal fluid α- synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimer's & Dementia. 2018 Aug 1;14(8):1052-62.

Sperling R, Johnson K. Biomarkers of Alzheimer d isease: current and future applicat ions to diagnostic criteria. CONTINUUM: Lifelong learning in neurology.

Rao CV, Asch AS, Carr DJ, Yamada HY. “Amyloid‐beta accumulation cycle” as a prevention and/or therapy target for Alzheimer's disease. Aging Cell. 2020 Mar;19(3):e13109.

Purba JS. PERAN INFLAMASI DAN AMILOID- BETA PADA PATOLOGI PENYAKIT ALZHEIMER. Neurona (Majalah Ked okteran Neuro Sains Perhimpuna n Dokter Spesialis Saraf Indonesia). 2011 Jul 1;28(4).

Rockwood K. Con: Can biomarkers be gold standards in Alzheimer's d isease?. Alzheimer's research & therapy. 2010 Jun;2(3):1-3.

Scheltens P, Rockwood K. How golden is the gold standard of neuropat hology in d ement ia?. Alzheimer's & Dementia. 2011 Jul 1;7(4):486-9.

Gordon D, Haynes C, Finch SJ, Brown AM. Increase in linkage information by stratification of pedigree data into gold-standard and standard diagnoses: application to the NIMH Alzheimer Disease Genetics Initiative Dataset. Human Heredity. 2006;61(2):97-103.




DOI: https://doi.org/10.26618/aimj.v3i2.4158

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Al-Iqra Medical Journal : Jurnal Berkala Ilmiah Kedokteran

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.